Metabolic profiling of target organic acids in Parkinson’s Disease using LC-ESI-MS by Karg, Rowan
Metabolic profiling of target organic acids in Parkinson’s Disease using LC-ESI-MS 
 
Author name: Rowan M.Y. Karg 
Name of institute: Leiden University, 
LACDR, SBP 
E-mail address: rowankarg@hotmail.com 
Supervisors: Dr. Edinson Lucumi Moreno & 
Cornelius Willacey 
ABSTRACT: 
To date, the exact cause of Parkinson’s disease (PD) 
is still unclear. Therefore, detection of newer targets 
which can be linked to the pathogenesis or 
progression of PD is vital. In this study, liquid 
chromatography-electrospray ionization-mass 
spectrometry was used (LC-ESI-MS) to detect target 
organic acid metabolites. In addition, metabolite 
levels were determined in three cell lines namely a 
healthy control, gene-corrected PD and PINK1 
mutant PD cell line. Several acids were successfully 
detected and results showed elevated levels of citric- 
and propanoic acid in the PINK1 mutant PD cell line 
compared to control groups. Further method 
improvement however is still necessary.  
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INTRODUCTION: 
The exact cause of the progressive neurodegenarative 
disorder Parkinson’s disease (PD) is still unclear and 
knowledge regarding its progression is also lacking. 
However, several hypotheses such as mitochondrial 
dysfunction, oxidative stress and genetic factors have 
been suggested as the most probable causes of PD 
[1]. In 5-10% of patient’s, genetic risk factors have 
been identified [2]. Mutations in the PTEN-induced 
kinase 1 (PINK1) gene can result in mitochondrial 
dysfunction and oxidative stress [3].  
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Patients seldomly experience PD symptoms such as 
tremor in early stages of the disease [4]. Therefore, 
early diagnosis of PD is essential to improve the 
quality of life at a younger age for patients. Earlier 
treatment also helps slow the progression of PD. This 
is however restricted as no biomarkers are available 
for the early identification of PD [5]. For this reason, 
identification of promising targets is essential as this 
enables the development of newer and improved 
treatments and specific biomarkers which may be 
used for the early diagnosis of PD [1]. Various 
approaches such as metabolomics can be used to 
investigate novel targets which may be linked to the 
diagnosis, pathogenesis and progression of PD [6]. 
The field of metabolomics is described as a wide-
ranged analysis and thorough characterization of up 
to thousands of metabolites.   
 
Current used analytical techniques in this field 
include liquid chromatography-electrospray 
ionization-mass spectrometry (LC-ESI-MS) for the 
analysis of complex biological samples [6]. The 
coupling of LC and ESI-MS ensures separation and 
ionization of metabolites prior to detection [6]. In 
addition, metabolites can be derivatized to increase 
specificity and sensitivity [7]. The aim of this 
research is to optimize and validate a LC-ESI-MS 
method for the detection of various target organic 
acid metabolites. The gathered metabolomics data 
will then be used to study the effect of a PINK1 gene 
mutation on the metabolite levels in three different 
cell lines namely a healthy control, gene-corrected 
PD (PD without the PINK1 mutation) and PINK1 
mutant PD cell line. Analyzing organic acid levels is 
vital as this can provide insight on underlying causes 
and symptoms of various illnesses and 
neurodegenerative disorders [8]. The following 
metabolites will be focused on during this research: 
acetic-, arachidonic-, citric-, dodecanoic-, formic-, 
fumaric-, lactic-, oxalic-, propanoic- and uric acid. 
These acids are implicated in either the mitochondrial 
dysfunction or oxidative stress hypothesis and are 
therefore promising targets.  
 
HYPOTHESIS: 
Uric acid has been associated with a decreased risk 
and slower progression of PD as it is believed to 
reduce oxidative stress [9]. Fumaric acid esters and 
fatty acids such as arachidonic- and dodecanoic acid 
have a neuroprotective role and are therefore capable 
of preventing mitochondrial dysfunction and 
reducing oxidative stress in PD [10]. Therefore, it is 
expected that levels of these four metabolites will be 
lower in the PD cell lines compared to the control 
group. The remaining acids have been linked to the 
impairment of the mitochondrial oxidative 
metabolism, leading to mitochondrial dysfunction 
and oxidative stress. Therefore, levels of these acids 
are expected to be higher in the PD cell lines 
compared to the control group . [11], [12]. This 
elevation could partially be triggered by the PINK1-
mutation, as this mutation has been a suspected cause 
of both mitochondrial dysfunction and the oxidative 
stress in PD [3]. 
 
MATERIAL AND METHODS: 
 
Standard stock solutions and buffer preparation: 
For each metabolite of interest, a 1 mg/ ml or 10 mg/ 
standard stock solution was prepared and further 
diluted using 50% DMSO/ 50% DMF. Furthermore, 
750 mM (100 ml) triethanolamine (TEOA) and 0,1 M 
(1 ml) sodium carbonate (Na2CO3) were prepared. 
The pH of TEOA and Na2CO3 was 10,0 and 12,5 
respectively. A 30 mg/ ml formic acid solution was 
also made to quench the derivatization reaction.  
 
Derivatization reaction: 10 μL of either TEOA or 
Na2CO3 was added to diluted samples. Subsequently, 
10 μL of the derivatization reagent dimethylamino 
phenacyl bromide (DmPaBr) was added (40 mg/ ml 
for TEOA samples; 60 mg/ ml for Na2CO3 samples). 
All samples were incubated for 1 hour (65°C). 
Afterwards, 20 μL formic acid (30 mg/ ml) was 
added, followed by incubation for another 30 
minutes. Lastly, 50 μL acetonitrile (ACN) was added 
and samples were centrifuged for 5 minutes. After 
derivatization, all samples were transferred to glass 
vials for LC-MS measurements.  
 
LC-ESI-MS: The Acquity UPLC system (Waters) 
and Triple Quad LC-MS series 6460 (Agilent 
Technologies were used. The mobile phase consisted 
of 0,1% formic acid 10 mM ammonium formate (A) 
and 100% ACN (B). Flow rate was gradually 
increased in 0,100 ml/ min increments up to 0,700 
ml/ min (10%A, 90%B). At 0,400 ml/ min the 
column temperature was switched from off to 60°C. 
Metabolites were detected using multiple reaction 
monitoring (MRM), a specific triple quadrupole MS 
technique which targets ions corresponding to the 
metabolites of interest. The principle of the MS is to 
detect ions based on their mass-to-charge (m/z) ratio. 
This data is then translated into the retention time 
(RT) which is the time ions need to pass through the 
column.  
 
Method validation: For each detected metabolite, 
the parameter linearity was validated using a seven-
point calibration curve with a concentration range of 
0,156 – 10 μg /ml (n = 1). The repeatability (%RSD) 
and limits of detection (LOD) were also determined 
(n = 4). 
 
PINK1 mutated PD stem cells: Cell lines were 
generated from human neuroepithelial stem cells 
(hNESCs) using induced pluripotent stem cells 
(iPSCs) technology. The hNESCs were then 
differentiated into dopaminergic neurons with- and 
without a PINK1 gene mutation. During this research 
three different cell lines were studied namely the K7 
healthy control line, 2122 gene-corrected PD (PD 
without the PINK1 mutation) and 2122 PD mutant 
cell line (PD with the PINK1 mutation). Using the 
distributed calibration curves, the concentration of 





Acetic-, citric- and propanoic acid were detected 
using TEOA as base. The RT of these acids was 3.35, 
5.12 and 3.88 minutes respectively. No considerable 
differences were seen with Na2CO3 for acetic- and 
propanoic acid. However, it was evident that citric 
acid was only detectable when TEOA is used, and 
not Na2CO3. Later on, three new metabolites were 
included namely arachidonic-, dodecanoic- and 
fumaric acid. These were also detected using TEOA 
as base and the observed RT was 6.72, 6.32 and 4.43 
minutes respectively.  
 
Undetected metabolites: 
Unfortunately, no usable results were produced for 
formic-, lactic-, oxalic- and uric acid. Detection of 
formic acid failed several times with both bases as 
high blanks were observed. Uric acid did not dissolve 
in DMSO/ DMF. When different solvents were used, 
it was observable that uric acid was soluble in KOH, 
however poorly soluble in water. Peaks were seen 
when using water as solvent; however, separation 
should be improved.  
 
Optimization of LC-ESI-MS method: 
The MRM method was optimized to solely include 
the precursor ion (m/z) of the detected metabolites as 
shown in Table 1. Using this optimized method, the 
RT was slighly different from previous 
measurements. Derivatization was done using 
DmPaBr and TEOA as base. The following MS 
parameters were used: product ion (m/z): 134 and 
180, Dwell: 50ms, Fragmentor: 135V, Collision 
energy: 20 eV, positive polarity, Gas Temp: 300°C. 
 
Method validation: 
The R2-value was calculated after the distribution of 
the calibration curves (Table 1). Propanoic acid had 
the highest R2 of 0,9965, whereas acetic acid had the 
lowest i.e. 0,8824. The parameters repeatability 
(%RSD) and limits of detection (LOD) were also 
validated (n = 4). Repeatability ranged from 8% - 
21%, with acetic acid having the lowest % and 
fumaric the highest (Table 1). The LOD ranged from 
2,0 – 6,4 nM, with arachidonic acid having the lowest 
LOD and fumaric acid the highest (Table 1 
PINK1 mutant PD cell line: 
The concentration of acetic acid in the three cell lines 
was not calculated due to a low R2-value. 
Arachidonic acid was not present in the cell media; 
thus, the concentration of this metabolite was also not 
calculated. The concentration of citric-, fumaric- and 
propanoic acid appears to be elevated in the PINK1 
mutant PD cell line compared to control groups 
(Figure 1). In contrast, the concentration of 
dodecanoic acid appears to be elevated the most in 
the control group, rather than the PINK1 mutated PD 
cell line.  
 
DISCUSSION: 
Uric acid proved insoluble in DMSO/ DMF. When 
dissolved in water, peaks were seen with LC-MS, 
however separation still needs improvement. The 
used composition of the mobile phase could have 
resulted in a bad separation and peak resolution of 
uric acid. In order to obtain a better resolution, the 
number of theoretical plates should be increased by 
extending the length of the column or by using  
a column with a smaller particle size [13]. Future LC-
MS measurements with uric acid should also be done 
preferably using solvents such as KOH [14]. 
Furthermore, it is possible that the undetected 
metabolites never hit the MS detector after being 
ionized [15]. Therefore, this could mean that the ion 
never passed through from the first quadrupole to the 
second, as only ions with the selected targeted mass 
are able to pass through when using a triple 
quadrupole MS [15]. To confirm this statement, a full 
scan with the MS or single ion monitoring (SIM) 
should be performed prior to using the MRM method.  
 
With the optimized LC-ESI-MS method, six 
metabolites were detected using TEOA as base. Good 
linearity was seen as an R2-value of > 0,98 was 
observed, except for acetic acid. However, 
measurements were not done in triplicates. Therefore, 
the number of samples per data point should be 
increased to at least n = 3 to gain a more accurate 
representation of the sample group and thus reliable 
validation. The repeatability was also validated and 
the limits of detection (LOD) was calculated for each 
metabolite (n = 4). The LOD is accepted when this is 
15-20% below the lowest limits of quantitation 
(LLOQ) [16]. However, the LLOQ could not be 
calculated due to the used small sample size. 
Therefore no conclusion can be made regarding the 
LOD of the studied metabolites.  
 
Lastly, the concentration of the detected metabolites 
was calculated in a healthy control, gene-corrected 
PD (PD without the PINK1 mutation) and PINK1 
mutant PD cell line. It was observed that the 
concentration of both citric- and propanoic acid was 
elevated in the PINK1 mutated PD cell line compared 
to control groups. This was expected, as previous 
studies had already linked elevated levels of citric 
acid to the impairment of the mitochondrial oxidative 
metabolism [11]. In this case, it is possible that the 
increased concentration of propanoic acid may have 
led to elevated levels of citric acid as more of 
succinyl-CoA is produced. When more of succinyl-
CoA is produced, enzymes responsible for the 
metabolization of citric acid are inhibited, leading to 
elevated levels of this metabolite [17]. The PINK1 
mutation could have negatively affected enzymes of 
the TCA cycle [18], hereby also inhibiting 
metabolization of citric acid, resulting in elevated 
levels. As less of citric acid is metabolized, less of 
NADH and FADH2 is produced [19]. Depleted levels 
of NADH and FADH2 could lead to an impaired 
complex 1 activity of the electron chain transport in 
PD [3]. This can lead to or further advance 
mitochondrial dysfunction.  
 
CONCLUSION: 
Based on the current research done, it can be 
concluded that a LC-ESI-MS method was optimized 
for the detection of five metabolites namely 
arachidonic-, citric-, dodecanoic-, fumaric- and 
propanoic acid using DmPaBr as derivatization 
reagent and TEOA as base. Furthermore, it can be 
concluded that method validation is still incomplete 
as a small sample size was used. Therefore, a larger 
sample size should be used and more parameters 
should be validated. This method should also be 
further expanded to include and detect more 
metabolites such as uric acid. These can then be 
studied to gain a better understanding of pathogenic 
mechanisms involved in disorders such as PD. By 
including more metabolites in the cell media, the 
potential role of these metabolites on the 
pathogenesis and progression of PD can be further 
studied in a broader context at cellular level. Based 
on the current results from the cell media it can be 
said that a mutation or loss of PINK1 leads to 
elevated concentrations of both citric- and propanoic 
acid. This enables future possibilities for continuing 
the investigation of a potential correlation between 
these two acids and the PINK1 mutation.  
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